Business Context and Reporting Period
This Form 8-K Current Report was filed by American BriVision (Holding) Corporation (also referenced as ABVC Biopharma, Inc.) on August 30, 2016, regarding events occurring on August 26, 2016. The filing discloses the entry into a Material Definitive Agreement and the unregistered sale of equity securities.
Key Financial Metrics
- Transaction Type: Private placement of common stock.
- Shares Issued: 1,468,750 shares.
- Purchase Price: $1.60 per share.
- Net Proceeds: Approximately $2,350,000.
- Use of Proceeds: General corporate purposes.
- Related Party Status: The purchaser, BioLite, Inc., is a related party as the Company's sole director, Eugene Jiang, also serves as a director of BioLite.
Material Changes
The filing reports a material change in the Company's capital structure through the issuance of new shares. The filing text does not provide comparative financial data (revenue, profit, cash flow, or margins) for the current or prior periods, as this is a transaction-specific report rather than a periodic financial statement.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosures related to the Stock Purchase Agreement (SPA). The SPA is filed as Exhibit 10.1 and contains customary representations and warranties. The transaction was exempt from registration under Regulation S of the Securities Act of 1933.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-transaction to assess dilution impact.
- Review the full text of the Stock Purchase Agreement (Exhibit 10.1) for specific covenants or restrictions.
- Confirm the current status of the "general corporate purposes" for which the $2.35 million in proceeds are intended.
- Assess the implications of the related-party transaction involving director Eugene Jiang.